New drug faricimab tested for hard-to-treat eye condition
Disease control
Not yet recruiting
This study tests the drug faricimab in 100 people aged 50 and older who have a specific form of age-related macular degeneration (AMD) called type 2 or mixed neovascular AMD with subretinal hyperreflective material (SHRM). The main goal is to see if faricimab can clear the SHRM b…
Phase: PHASE4 • Sponsor: Biobizkaia Health Research Institute • Aim: Disease control
Last updated May 14, 2026 12:02 UTC